166 related articles for article (PubMed ID: 37502956)
1. NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer.
Li JJ; Vasciaveo A; Karagiannis D; Sun Z; Chen X; Socciarelli F; Frankenstein Z; Zou M; Pannellini T; Chen Y; Gardner K; Robinson BD; de Bono J; Abate-Shen C; Rubin MA; Loda M; Sawyers CL; Califano A; Lu C; Shen MM
bioRxiv; 2023 Jul; ():. PubMed ID: 37502956
[TBL] [Abstract][Full Text] [Related]
2. The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity.
Storck WK; May AM; Westbrook TC; Duan Z; Morrissey C; Yates JA; Alumkal JJ
Front Endocrinol (Lausanne); 2022; 13():926585. PubMed ID: 35909568
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.
Bhagirath D; Liston M; Patel N; Akoto T; Lui B; Yang TL; To DM; Majid S; Dahiya R; Tabatabai ZL; Saini S
Oncogene; 2020 Dec; 39(49):7209-7223. PubMed ID: 33037409
[TBL] [Abstract][Full Text] [Related]
4. Development of Neuroendocrine Prostate Cancers by the Ser/Arg Repetitive Matrix 4-Mediated RNA Splicing Network.
Lee AR; Che N; Lovnicki JM; Dong X
Front Oncol; 2018; 8():93. PubMed ID: 29666783
[TBL] [Abstract][Full Text] [Related]
5. Reprogramming landscape highlighted by dynamic transcriptomes in therapy-induced neuroendocrine differentiation.
Asberry AM; Liu S; Nam HS; Deng X; Wan J; Hu CD
Comput Struct Biotechnol J; 2022; 20():5873-5885. PubMed ID: 36382181
[TBL] [Abstract][Full Text] [Related]
6. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
[No Abstract] [Full Text] [Related]
7. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
8. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.
Brennen WN; Zhu Y; Coleman IM; Dalrymple SL; Antony L; Patel RA; Hanratty B; Chikarmane R; Meeker AK; Zheng SL; Hooper JE; Luo J; De Marzo AM; Corey E; Xu J; Yegnasubramanian S; Haffner MC; Nelson PS; Nelson WG; Isaacs WB; Isaacs JT
JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33724955
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
[TBL] [Abstract][Full Text] [Related]
10. LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancer.
Mandl A; Jasmine S; Krueger T; Kumar R; Coleman IM; Dalrymple SL; Antony L; Rosen DM; Jing Y; Hanratty B; Patel RA; Jin-Yih L; Dias J; Celatka CA; Tapper AE; Kleppe M; Kanayama M; Speranzini V; Wang YZ; Luo J; Corey E; Sena LA; Casero RA; Lotan T; Trock BJ; Kachhap SK; Denmeade SR; Carducci MA; Mattevi A; Haffner MC; Nelson PS; Rienhoff HY; Isaacs JT; Brennen WN
bioRxiv; 2024 Jan; ():. PubMed ID: 38328141
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of RACGAP1 by E2F1 Promotes Neuroendocrine Differentiation of Prostate Cancer by Stabilizing EZH2 Expression.
Song Z; Cao Q; Guo B; Zhao Y; Li X; Lou N; Zhu C; Luo G; Peng S; Li G; Chen K; Wang Y; Ruan H; Guo Y
Aging Dis; 2023 Oct; 14(5):1757-1774. PubMed ID: 37196108
[TBL] [Abstract][Full Text] [Related]
12. RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer.
Labrecque MP; Brown LG; Coleman IM; Lakely B; Brady NJ; Lee JK; Nguyen HM; Li D; Hanratty B; Haffner MC; Rickman DS; True LD; Lin DW; Lam HM; Alumkal JJ; Corey E; Nelson PS; Morrissey C
Cancer Res; 2021 Sep; 81(18):4736-4750. PubMed ID: 34312180
[TBL] [Abstract][Full Text] [Related]
13. Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution.
Imamura J; Ganguly S; Muskara A; Liao RS; Nguyen JK; Weight C; Wee CE; Gupta S; Mian OY
Front Endocrinol (Lausanne); 2023; 14():1191311. PubMed ID: 37455903
[TBL] [Abstract][Full Text] [Related]
14. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
[TBL] [Abstract][Full Text] [Related]
15. Expression of Fibroblast Activation Protein Is Enriched in Neuroendocrine Prostate Cancer and Predicts Worse Survival.
Vlachostergios PJ; Karathanasis A; Tzortzis V
Genes (Basel); 2022 Jan; 13(1):. PubMed ID: 35052475
[TBL] [Abstract][Full Text] [Related]
16. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
Schalken J; Fitzpatrick JM
BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596
[TBL] [Abstract][Full Text] [Related]
17. Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype.
Filon M; Gawdzik J; Truong A; Allen G; Huang W; Khemees T; Machhi R; Lewis P; Yang B; Denu J; Jarrard D
Br J Cancer; 2021 Jul; 125(2):247-254. PubMed ID: 33976366
[TBL] [Abstract][Full Text] [Related]
18. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
[TBL] [Abstract][Full Text] [Related]
19. Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.
Dang Q; Li L; Xie H; He D; Chen J; Song W; Chang LS; Chang HC; Yeh S; Chang C
Mol Oncol; 2015 Aug; 9(7):1241-51. PubMed ID: 25817444
[TBL] [Abstract][Full Text] [Related]
20. Dual-Acting Peptides Target EZH2 and AR: A New Paradigm for Effective Treatment of Castration-Resistant Prostate Cancer.
Han Z; Rimal U; Khatiwada P; Brandman J; Zhou J; Hussain M; Viola RE; Shemshedini L
Endocrinology; 2022 Nov; 164(1):. PubMed ID: 36288553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
